课题基金 / 基金详情

Regulation of and by the Myc Oncoprotein

Regulation of and by the Myc Oncoprotein
Myc 癌蛋白的调节和调节
批准号:
6922090
负责人:
Edward Victor Prochownik
金额:
$29.42万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-15 至 2009-04-30

项目摘要

项目成果

Edward Victor Prochownik的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):Myc癌蛋白网络调节细胞周期进程、生长、分化、凋亡和基因组完整性。c-Myc是家族的原型成员,其去调控在许多恶性肿瘤中普遍发生,并且总是与基因组不稳定和继发性突变相关。了解c-Myc活性的分子基础将涉及表征与其相互作用的蛋白质,表征其控制下的基因产物,并确定它们在介导c-Myc的多种表型中的作用。在第一个方面,我们最近发现了一种新的蛋白,PAG或过氧化物还氧蛋白1,它与c-Myc的转录激活域相互作用。PAG抑制c-Myc的转化,同时保持甚至增强其其他活性。PAG保护细胞免受DNA氧化损伤,是一种肿瘤抑制因子。我们还确定了c-Myc的一个新的转录靶点,称为MT-MC1,其过度表达模仿了c-Myc的许多表型特性,包括转化、改变细胞形态、促进细胞凋亡、抑制分化、促进基因组不稳定性和调节一些c-Myc靶基因的能力。MT-MC1的许多特性与c- myc无关。因此,MT-MC1凭借其调节多种c-Myc功能的能力,在c-Myc信号通路中起着关键和近端作用。最近的证据还表明,c-Myc、PAG和MT-MC1在调节细胞对氧化应激反应的能力方面存在功能和生化联系。这种压力引起的DNA损伤可能是肿瘤产生和/或进化的主要原因。在本应用的第一个具体目标中,我们提出了进一步研究PAG的建议。这些包括确定其与c-Myc无关的功能,鉴定与其相互作用的新蛋白质,确定其与c-Myc相互作用所需的区域,以及进一步表征PAG敲除小鼠品系。这些小鼠将与一种新的c- myc介导的肿瘤发生、消退和自发复发的体内诱导模型(Tet-Myc小鼠)结合使用。在第二个具体目标中,我们提出了对MT-MC1的进一步研究。我们将研究MT-MC1在原代细胞中的作用,将鉴定新的MT-MC1相互作用蛋白,将进一步研究MT-MC1多种功能的模块化性质,并将创建一个条件MT-MC1“敲除”小鼠品系。这些动物与PAG-/-小鼠或Tet-Myc小鼠的杂交将有助于进一步在体内确定c-Myc、PAG和MT-MC1之间的三向连接。
英文摘要
DESCRIPTION (provided by applicant): The Myc oncoprotein network modulates cell cycle progression, growth, differentiation, apoptosis, and genomic integrity. De-regulation of c-Myc, the prototype member of the family, occurs commonly in many malignancies and is invariably associated with genomic instability and secondary mutations. Understanding the molecular basis for c-Myc's activities will involve characterizing proteins with which it interacts, characterizing the gene products under its control, and determining their roles in mediating c-Myc's multiple phenotypes. Toward the first of these ends, we have recently identified a novel protein, PAG, or peroxiredoxin 1, that interacts with the transcriptional activation domain of c-Myc. PAG inhibits transformation by c-Myc while preserving or even enhancing its other activities. PAG protects cells against oxidative DNA damage and is a tumor suppressor. We have also identified a new transcriptional target for c-Myc, termed MT-MC1, whose over-expression mimics many of the phenotypic properties of c-Myc, including the ability to transform, to alter cellular morphology, to promote apoptosis, to inhibit differentiation, to promote genomic instability, and to regulate some c-Myc target genes. Many of MT-MC1's properties are c-Myc-independent. MT-MC1 thus plays a critical and proximal role in the c-Myc signaling pathway by virtue of its ability to regulate multiple c-Myc functions. Recent evidence also suggests a functional and biochemical connection among c-Myc, PAG, and MT-MC1 with regard to their ability to modulate the response of cells to oxidative stress. Damaged DNA arising from such stress may be a major contributor to tumor generation and/or evolution. In the First Specific Aim of this application, we propose further studies with PAG. These include defining its c-Myc-independent functions, identifying novel proteins with which it interacts, defining the regions necessary for its interaction with c- Myc, and further characterizing a PAG knockout mouse strain. These mice will be used in conjunction with a novel inducible in vivo model of c-Myc-mediated tumorigenesis, regression, and spontaneous recurrence (Tet-Myc mice). In the Second Specific Aim, we propose further studies with MT-MC1. We will examine the effect of MT-MC1 in primary cells, will identify novel MT-MC1-interacting proteins, will further investigate the modular nature of MT-MC1's multiple functions, and will create a conditional MT-MC1 "knockout" mouse strain. Crosses between these animals and either PAG-/- mice or Tet-Myc mice will help to further define in vivo the proposed three-way connection among c-Myc, PAG, and MT-MC1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Control of Metabolism and Energy-Sensing Pathways by c-Myc
Control of Metabolism and Energy-Sensing Pathways by c-Myc
Structure-based design of novel low molecular weight c-Myc inhibitors
Structure-based design of novel low molecular weight c-Myc inhibitors
海外基金